We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+33.19%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.8B
AUM Growth
+$158M
(+6%)
Cap. Flow
-$258M
Cap. Flow
% of AUM
-9.21%
Top 10 Holdings %
Top 10 Hldgs %
41.71%
Holding
75
New
23
Increased
16
Reduced
15
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$125M |
| 2 |
Teleflex
TFX
|
+$107M |
| 3 |
HOLX
Hologic
HOLX
|
+$82.4M |
| 4 |
Envista
NVST
|
+$72.4M |
| 5 |
Labcorp
LH
|
+$63.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$124M |
| 2 |
Edwards Lifesciences
EW
|
+$115M |
| 3 |
Baxter International
BAX
|
+$90.3M |
| 4 |
Merck
MRK
|
+$88.2M |
| 5 |
CVRS
CORINDUS VASCULAR ROBOTICS, INC
CVRS
|
+$85.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.07% |
| 2 | Technology | 1.67% |
| 3 | Industrials | 0.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Illumina
ILMN
$31B
| $48.4M | 1.73% |
+149,975
| New | +$45.5M |
|
|
CHNG
27
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $46.7M | 1.67% |
2,849,650
-1,404,780
| -33% | -$18.8M |
|
28
IQVIA
IQV
$38.7B
| $44M | 1.57% |
284,530
+10,580
| +4% | +$1.54M |
|
29
Axsome Therapeutics
AXSM
$11.2B
| $42.2M | 1.51% |
+408,617
| New | +$16.5M |
|
|
VRAY
30
DELISTED
ViewRay, Inc.
VRAY
| $40M | 1.43% |
9,477,799
+4,587,699
| +94% | +$14.8M |
|
31
Centene
CNC
$30.7B
| $35.3M | 1.26% |
+560,900
| New | +$30.4M |
|
32
Pacira BioSciences
PCRX
$1.04B
| $34.9M | 1.25% |
+771,140
| New | +$32.8M |
|
33
Cigna
CI
$73.7B
| $34.5M | 1.23% |
+168,730
| New | +$30.9M |
|
|
AMRN
34
Amarin Corp
AMRN
$299M
| $33.5M | 1.19% |
+78,054
| New | +$29.6M |
|
35
Agios Pharmaceuticals
AGIO
$1.79B
| $33.3M | 1.19% |
+697,390
| New | +$26.4M |
|
|
ZGNX
36
DELISTED
Zogenix, Inc.
ZGNX
| $32.2M | 1.15% |
618,550
+487,560
| +372% | +$22.3M |
|
|
37
Edwards Lifesciences
EW
$49.6B
| $31.1M | 1.11% |
399,630
-1,478,340
| -79% | -$115M |
|
38
Pediatrix Medical
MD
$2.18B
| $29.9M | 1.07% |
+1,074,480
| New | +$26.9M |
|
39
Charles River Laboratories
CRL
$11.2B
| $26.7M | 0.95% |
175,000
-190,360
| -52% | -$26.4M |
|
|
BPMC
40
DELISTED
Blueprint Medicines
BPMC
| $24.7M | 0.88% |
308,538
-300,879
| -49% | -$22.5M |
|
41
Gilead Sciences
GILD
$162B
| $18.4M | 0.66% |
283,520
-199,410
| -41% | -$13M |
|
|
XLRN
42
DELISTED
Acceleron Pharma
XLRN
| $17.1M | 0.61% |
+322,540
| New | +$14.7M |
|
|
43
Vertex Pharmaceuticals
VRTX
$121B
| $14.4M | 0.51% |
65,860
-613,830
| -90% | -$124M |
|
|
HMSY
44
DELISTED
HMS Holdings Corp.
HMSY
| $13.7M | 0.49% |
+463,390
| New | +$14.2M |
|
45
Stryker
SYK
$125B
| $13.5M | 0.48% |
64,170
-22,920
| -26% | -$4.76M |
|
46
PUT
Eli Lilly
LLY
$1.02T
| $13.1M | 0.47% |
+100,000
| New | +$11.6M |
|
47
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
| $10.2M | 0.36% |
+100,000
| New | +$9.61M |
|
|
BMY.RT
48
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $9.46M | 0.34% |
+3,141,841
| New | +$8.17M |
|
49
Rocket Pharmaceuticals
RCKT
$340M
| $8.84M | 0.32% |
+388,360
| New | +$6.49M |
|
|
AERI
50
DELISTED
Aerie Pharmaceuticals
AERI
| $7.31M | 0.26% |
+302,290
| New | +$6.26M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q4 2019 Portfolio in Review
As of Q4 2019, HealthCor Management held 75 positions worth $2.8B, up 6% from $2.65B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
HealthCor Management withdrew a net $258M in Q4 2019, closing 19 positions and reducing 15 holdings. Its most notable exit was Baxter International, an estimated $90.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 90% a quarter earlier, followed by Technology and Industrials.
Against the trend, HealthCor Management opened a new position in Regeneron Pharmaceuticals worth $140M.
- HealthCor Management's largest Q4 2019 buy was Regeneron Pharmaceuticals: 372,770 shares worth $140M.
- HealthCor Management added most to Hologic in Q4 2019, an estimated $82.4M increase.
- HealthCor Management's biggest Q4 2019 reduction was Vertex Pharmaceuticals, cutting an estimated $124M.
- HealthCor Management fully exited Baxter International in Q4 2019, selling an estimated $90.3M.
- HealthCor Management's ten largest holdings make up 42% of its $2.8B portfolio in Q4 2019.
- HealthCor Management opened 23 new positions and closed 19 in Q4 2019.
- HealthCor Management's portfolio value rose 6% quarter-over-quarter to $2.8B.
Based on HealthCor Management's 13F filing for Q4 2019, filed 14 Feb 2020.